norfloxacin has been researched along with diclofenac in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (27.78) | 29.6817 |
2010's | 12 (66.67) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Avdeef, A; Tam, KY | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF | 1 |
Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
Caljon, G; Cappoen, D; Claes, P; Cools, F; Cos, P; De Kimpe, N; de Macedo, MB; Delputte, P; Holvoet, F; Maes, L; Mangelinckx, S; Matheeussen, A; Meiresonne, T; Neyrolles, O; Piller, T; Semina, E; Torfs, E; Van Calster, K | 1 |
Barbosa, G; Ceschi, MA; Dantas, RF; Dardenne, LE; de Salles, CMC; Guedes, IA; Lima, LM; Lopes, JPB; Lüdtke, DS; Ruaro, TC; Senger, MR; Silva, L; Silva-Jr, FP; Zimmer, AR | 1 |
Alagarsamy, V; Murugananthan, G; Venkateshperumal, R | 1 |
Bhanger, MI; Khuhawar, MY; Mallah, A; Memon, SQ; Solangi, AR | 1 |
Kim, J; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
Cruz-Monzon, J; De La Cruz-Noriega, M; Gallozzo Cardenas, M; Gamez-Jara, A; Rodríguez-Serin, H; Rodriguez-Yupanqui, M; Rojas-Flores, S | 1 |
3 review(s) available for norfloxacin and diclofenac
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recently reported biological activities of pyrazole compounds.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles | 2017 |
Literature Review: Evaluation of Drug Removal Techniques in Municipal and Hospital Wastewater.
Topics: Anti-Bacterial Agents; Carbamazepine; Diclofenac; Hospitals; Naproxen; Norfloxacin; Ofloxacin; Ozone; Pharmaceutical Preparations; Sewage; Sulfamethoxazole; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2022 |
15 other study(ies) available for norfloxacin and diclofenac
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzophenanthridines; Cell Line; Dose-Response Relationship, Drug; Humans; Hydrocarbons, Fluorinated; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2019 |
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
Topics: | 2019 |
Synthesis, analgesic, anti-inflammatory and antibacterial activities of some novel 2-methyl-3-substituted quinazolin-4-(3H)-ones.
Topics: Administration, Oral; Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Diclofenac; Disease Models, Animal; Drug Administration Schedule; Female; Foot; Gram-Negative Bacteria; Gram-Positive Bacteria; Inflammation; Male; Microbial Sensitivity Tests; Norfloxacin; Oxazines; Pain; Pain Measurement; Quinazolines; Rats; Rats, Wistar; Time Factors | 2003 |
Quantitative separation of oxytocin, norfloxacin and diclofenac sodium in milk samples using capillary electrophoresis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Borates; Buffaloes; Diclofenac; Electrophoresis, Capillary; Female; Hydrogen-Ion Concentration; Linear Models; Milk; Norfloxacin; Oxytocics; Oxytocin; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin; Diclofenac; Dioxolanes; Drug Combinations; Drug Interactions; Enoxacin; Fleroxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Male; Mice; Microbial Sensitivity Tests; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Phenylacetates; Piperazines; Receptors, GABA-A; Seizures | 2009 |
Diclofenac inferior to norfloxacin for symptom relief of lower UTIs.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Disease Progression; Female; Humans; Norfloxacin; Randomized Controlled Trials as Topic; Urinary Tract Infections | 2018 |